SPP1 and colorectal carcinoma: Previous studies [48] have shown that SPP1 inhibits T-cell activation by binding CD44 and contributes to immune tolerance in CRC; therefore, targeting SPP1 signaling is a promising therapeutic option for CRC, especially in patients of yCRC.